BioCentury
ARTICLE | Finance

Burgeoning bellwethers

26th annual Buyside View sees biotech investors eyeing small- and mid-caps in 2018

January 6, 2018 12:38 AM UTC

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one.

Buysiders spent most of 2017 focusing to a large degree on the big caps, which had been riding clinical data and commercial launches to new heights. Biotechs valued at $10 billion and up had a median gain in value of 16.1% through 3Q17, adding $248.4 billion in market cap in the first nine months of the year. ...